The Role of SGLT2 Inhibitors in the Management of T2DM

Friday, October 20, 2017 at 11:00 AM

SGLT-2 inhibitors lower glucose levels and blood pressure, improve cardiovascular disease (CVD) outcomes, and slow renal decline.

For this reason, healthcare providers should consider using empagliflozin in all appropriate patients with type 2 diabetes and preexisting CVD, according to Anne L Peters, MD, who will discuss the subject further in her presentation “The Role of SGLT-2 Inhibitors in the Management of T2DM.”

Peters will review the process of glucose metabolism, as well as detail the many SGLT-2 inhibitors available for use today. Specifically, she will address the question, “Are there clinically meaningful differences among available agents?,”  and review the effects of treatment with empagliflozin and canagliflozin on various outcomes, including blood pressure, CV death, renal function, HbA1c, and hospitalization for heart failure.

She will review the role of treatment with SGLT2 inhibitors in current guidelines, and important considerations to examine before beginning SGLT2 inhibitor therapy.

—Michael Potts

Reference:

Peters A. The Role of SGLT2 Inhibitors in the Management of T2DM [presented at Cardiometabolic Risk Summit]. Dallas, Texas. Friday, October 20, 2017.